Mergers & Acquisitions ·
Repligen completes acquisition of BioLife for $11.25 cash and 0.1442 shares of Repligen stock per share
BLFSBiolife Solutions Inc
On October 6, 2026, Repligen Corporation completed its previously announced acquisition of BioLife Solutions, Inc., pursuant to the Agreement and Plan of Merger dated July 21, 2026. Upon closing, each outstanding share of BioLife common stock converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock. All BioLife directors and named executive officers resigned effective immediately upon the merger's completion. As a result of the transaction, BioLife ceased to exist as a separate legal entity, its common stock was delisted from Nasdaq, and it became a wholly owned subsidiary of Repligen. The company operates in the bioprocessing industry, providing solutions for cell therapy and vaccine manufacturing.